Targeting of IL-4 and IL-13 receptors for cancer therapy

Cytokine

Volumn 75, Issue 1, 2015, Pages 79-88

  Suzuki, Akiko ^a,b   Leland, Pamela ^a   Joshi, Bharat H ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Interleukin 13; Interleukin 13 receptor; Interleukin 4; Interleukin 4 receptor; Receptor targeted cancer therapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; DOXORUBICIN; IMMUNOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; LIPOSOME; STAT6 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTIGEN; ANTINEOPLASTIC AGENT; IL4R PROTEIN, HUMAN; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN-13 RECEPTOR, HUMAN; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR MARKER;

BONE MARROW CELL; BREAST CANCER; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LEWIS CARCINOMA; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METASTASIS; MOUSE; NEOPLASM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MICE; NEOPLASM METASTASIS; NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTORS, INTERLEUKIN-13;

EID: 84938985048     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.05.026     Document Type: Review

References (154)

1. Murata T., Obiri N.I., Puri R.K. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med 1998, 1(3):551-557.
2. Puri R.K., Leland P., Obiri N.I., Husain S.R., Kreitman R.J., Haas G.P., et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996, 87(10):4333-4339.
3. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12(1):99-106.
4. Minty A., Chalon P., Derocq J.M., Dumont X., Guillemot J.C., Kaghad M., et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993, 362(6417):248-250.
5. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000, 1(6):515-520.
6. Koller F.L., Hwang D.G., Dozier E.A., Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 2010, 31(6):1010-1017.
7. de Waal Malefyt R., Abrams J.S., Zurawski S.M., Lecron J.C., Mohan-Peterson S., Sanjanwala B., et al. Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 1995, 7(9):1405-1416.
8. Aversa G., Punnonen J., Cocks B.G., de Waal Malefyt R., Vega F., Zurawski S.M., et al. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13- induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993, 178(6):2213-2218.
9. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993, 151(11):6370-6381.
10. McKenzie A.N., Culpepper J.A., de Waal Malefyt R., Briere F., Punnonen J., Aversa G., et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993, 90(8):3735-3739.
11. Punnonen J., Aversa G., Cocks B.G., McKenzie A.N., Menon S., Zurawski G., et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993, 90(8):3730-3734.
12. Cocks B.G., de Waal Malefyt R., Galizzi J.P., de Vries J.E., Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 1993, 5(6):657-663.
13. Defrance T., Carayon P., Billian G., Guillemot J.C., Minty A., Caput D., et al. Interleukin 13 is a B cell stimulating factor. J Exp Med 1994, 179(1):135-143.
14. Zurawski G., de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994, 15(1):19-26.
15. Zurawski G., de Vries J.E. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cell 1994, 12(2):169-174.
16. Joshi B.H., Leland P., Lababidi S., Varrichio F., Puri R.K. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med 2014.
17. Prokopchuk O., Liu Y., Henne-Bruns D., Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005, 92(5):921-928.
18. Todaro M., Lombardo Y., Francipane M.G., Alea M.P., Cammareri P., Iovino F., et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 2008, 15(4):762-772.
19. Barderas R., Bartolome R.A., Fernandez-Acenero M.J., Torres S., Casal J.I. High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res 2012, 72(11):2780-2790.
20. Fujisawa T., Joshi B., Nakajima A., Puri R.K. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009, 69(22):8678-8685.
21. Fujisawa T., Joshi B.H., Puri R.K. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012, 131(2):344-356.
22. Nguyen V., Conyers J.M., Zhu D., Gibo D.M., Dorsey J.F., Debinski W., et al. IL-13Ralpha2-targeted therapy escapees: biologic and therapeutic implications. Translational Oncol 2011, 4(6):390-400.
23. Nakashima H., Terabe M., Berzofsky J.A., Husain S.R., Puri R.K. A novel combination immunotherapy for cancer by IL-13Ralpha2-targeted DNA vaccine and immunotoxin in murine tumor models. J Immunol 2011, 187(10):4935-4946.
24. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008, 18(1):11-18.
25. Wang H.W., Joyce J.A. Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 2010, 9(24):4824-4835.
26. Murata T., Taguchi J., Puri R.K. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998, 91(10):3884-3891.
27. Murata T., Noguchi P.D., Puri R.K. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996, 156(8):2972-2978.
28. Murata T., Husain S.R., Mohri H., Puri R.K. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 1998, 10(8):1103-1110.
29. Murata T., Puri R.K. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cellular Immunol 1997, 175:33-40.
30. Kohler I., Alliger P., Rieber E.P. Activation of gene transcription by IL-4, IL-13 and IFN-gamma through a shared DNA binding motif. Behring Inst Mitt 1995, 96:78-86.
31. Kohler I., Alliger P., Minty A., Caput D., Ferrara P., Holl-Neugebauer B., et al. Human interleukin-13 activates the interleukin-4-dependent transcription factor NF-IL4 sharing a DNA binding motif with an interferon-gamma-induced nuclear binding factor. FEBS Lett 1994, 345(2-3):187-192.
32. Lin J.X., Migone T.S., Tsang M., Friedmann M., Weatherbee J.A., Zhou L., et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995, 2(4):331-339.
33. Hershey G.K. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003, 111(4):677-690. (quiz 691).
34. Kelly-Welch A., Hanson E.M., Keegan A.D. Interleukin-4 (IL-4) pathway. Sci's STKE: Signal Transduct Knowl Environ 2005, 2005(293):cm9.
35. Luzina I.G., Keegan A.D., Heller N.M., Rook G.A., Shea-Donohue T., Atamas S.P. Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukoc Biol 2012, 92(4):753-764.
36. Murata T., Puri R.K. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell Immunol 1997, 175(1):33-40.
37. Murata T., Obiri N.I., Puri R.K. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997, 70(2):230-240.
38. Wood N., Whitters M.J., Jacobson B.A., Witek J., Sypek J.P., Kasaian M., et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med 2003, 197(6):703-709.
39. Rahaman S.O., Sharma P., Harbor P.C., Aman M.J., Vogelbaum M.A., Haque S.J. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002, 62(4):1103-1109.
40. Rahaman S.O., Vogelbaum M.A., Haque S.J. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res 2005, 65(7):2956-2963.
41. Kioi M., Kawakami K., Puri R.K. Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R. Cell Immunol 2004, 229(1):41-51.
42. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008, 132(2):259-272.
43. Wills-Karp M., Finkelman F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008, 1(51):pe55.
44. Heller N.M., Qi X., Junttila I.S., Shirey K.A., Vogel S.N., Paul W.E., et al. Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal 2008, 1(51):ra17.
45. Obiri N.I., Debinski W., Leonard W.J., Puri R.K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995, 270(15):8797-8804.
46. Kemp R.A., Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001, 167(11):6497-6502.
47. Stremmel C., Greenfield E.A., Howard E., Freeman G.J., Kuchroo V.K. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med 1999, 189(6):919-930.
48. Espana L., Martin B., Aragues R., Chiva C., Oliva B., Andreu D., et al. Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Am J Pathol 2005, 167(4):1125-1137.
49. Stassi G., Todaro M., Zerilli M., Ricci-Vitiani L., Di Liberto D., Patti M., et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003, 63(20):6784-6790.
50. Obiri N.I., Hillman G.G., Haas G.P., Sud S., Puri R.K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Investig 1993, 91(1):88-93.
51. Toi M., Bicknell R., Harris A.L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992, 52(2):275-279.
52. Golumbek P.T., Lazenby A.J., Levitsky H.I., Jaffee L.M., Karasuyama H., Baker M., et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991, 254(5032):713-716.
53. Cascinelli N., Foa R., Parmiani G., Arienti F., Belli F., Bernengo M.G., et al. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. Hum Gene Ther 1994, 5(8):1059-1064.
54. Sosman J.A., Bartemes K., Offord K.P., Kita H., Fisher S.G., Kefer C., et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res: Off J Am Assoc Cancer Res 1995, 1(8):805-812.
55. Sosman J.A., Fisher S.G., Kefer C., Fisher R.I., Ellis T.M. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 1994, 5(5):447-452.
56. Stadler W.M., Rybak M.E., Vogelzang N.J. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 1995, 76(9):1629-1633.
57. Whitehead R.P., Unger J.M., Goodwin J.W., Walker M.J., Thompson J.A., Flaherty L.E., et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother 1998, 21(6):440-446.
58. Tepper R.I., Levinson D.A., Stanger B.Z., Campos-Torres J., Abbas A.K., Leder P. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1990, 62(3):457-467.
59. Hock H., Dorsch M., Kunzendorf U., Qin Z., Diamantstein T., Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993, 90(7):2774-2778.
60. Francipane M.G., Alea M.P., Lombardo Y., Todaro M., Medema J.P., Stassi G. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res 2008, 68(11):4022-4025.
61. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1(4):389-402.
62. Volonte A., Di Tomaso T., Spinelli M., Todaro M., Sanvito F., Albarello L., et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol 2014, 192(1):523-532.
63. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16(2):91-102.
64. Kobayashi M., Kobayashi H., Pollard R.B., Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998, 160(12):5869-5873.
65. Asselin-Paturel C., Echchakir H., Carayol G., Gay F., Opolon P., Grunenwald D., et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998, 77(1):7-12.
66. Nakagomi H., Pisa P., Pisa E.K., Yamamoto Y., Halapi E., Backlin K., et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995, 63(3):366-371.
67. Burt B.M., Bader A., Winter D., Rodig S.J., Bueno R., Sugarbaker D.J. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18(6):1568-1577.
68. Zelba H., Weide B., Martens A., Derhovanessian E., Bailur J.K., Kyzirakos C., et al. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. Clin Cancer Res: Off J Am Assoc Cancer Res 2014, 20(16):4390-4399.
69. Kwon M., Kim J.W., Roh J.L., Park Y., Cho K.J., Choi S.H., et al. Recurrence and cancer-specific survival according to the expression of IL-4Ralpha and IL-13Ralpha1 in patients with oral cavity cancer. Eur J Cancer 2014.
70. Yang C.M., Chen H.C., Hou Y.Y., Lee M.C., Liou H.H., Huang S.J., et al. A high IL-4 production diplotype is associated with an increased risk but better prognosis of oral and pharyngeal carcinomas. Arch Oral Biol 2014, 59(1):35-46.
71. Obiri N.I., Leland P., Murata T., Debinski W., Puri R.K. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 1997, 158(2):756-764.
72. Debinski W., Obiri N.I., Powers S.K., Pastan I., Puri R.K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res: Off J Am Assoc Cancer Res 1995, 1(11):1253-1258.
73. Debinski W., Puri R.K., Kreitman R.J., Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Chem 1993, 268(19):14065-14070.
74. Husain S.R., Obiri N.I., Gill P., Zheng T., Pastan I., Debinski W., et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res: Off J Am Assoc Cancer Res 1997, 3(2):151-156.
75. Joshi B.H., Kawakami K., Leland P., Puri R.K. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res: Off J Am Assoc Cancer Res 2002, 8(6):1948-1956.
76. Shimamura T., Fujisawa T., Husain S.R., Joshi B., Puri R.K. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res: Off J Am Assoc Cancer Res 2010, 16(2):577-586.
77. Joshi B.H., Puri R.K. IL-13 receptor-alpha2: a novel target for cancer therapy. Immunotherapy 2009, 1(3):321-327.
78. Puri S., Puri S., Mahapatra A.K., Hussain E., Sarkar C., Sinha S., et al. A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. Curr Mol Med 2009, 9(6):732-739.
79. Obiri N.I., Murata T., Debinski W., Puri R.K. Modulation of interleukin (IL)-13 binding and signaling by the gamma c chain of the IL-2 receptor. J Biol Chem 1997, 272(32):20251-20258.
80. Kawakami K., Taguchi J., Murata T., Puri R.K. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001, 97(9):2673-2679.
81. Fujisawa T., Nakashima H., Nakajima A., Joshi B.H., Puri R.K. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 2011, 128(5):1221-1231.
82. Arima K., Sato K., Tanaka G., Kanaji S., Terada T., Honjo E., et al. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem 2005, 280(26):24915-24922.
83. Hsi L.C., Kundu S., Palomo J., Xu B., Ficco R., Vogelbaum M.A., et al. Silencing IL-13Ralpha2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther 2011, 10(7):1149-1160.
84. Viita H., Pacholska A., Ahmad F., Tietavainen J., Naarala J., Hyvarinen A., et al. 15-Lipoxygenase-1 induces lipid peroxidation and apoptosis, and improves survival in rat malignant glioma. In Vivo 2012, 26(1):1-8.
85. Mandal D., Levine A.D. Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis 2010, 16(5):753-764.
86. Ko C.W., Cuthbert R.J., Orsi N.M., Brooke D.A., Perry S.L., Markham A.F., et al. Lack of interleukin-4 receptor alpha chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice. J Pathol 2008, 214(5):603-609.
87. Ingram N., Northwood E.L., Perry S.L., Marston G., Snowden H., Taylor J.C., et al. Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations. Carcinogenesis 2013, 34(10):2341-2349.
88. Puri R.K., Debinski W., Obiri N., Kreitman R., Pastan I. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin. Cell Immunol 1994, 154(1):369-379.
89. Puri R.K., Leland P., Kreitman R.J., Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994, 58(4):574-581.
90. Husain S.R., Behari N., Kreitman R.J., Pastan I., Puri R.K. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res 1998, 58(16):3649-3653.
91. Ishige K., Shoda J., Kawamoto T., Matsuda S., Ueda T., Hyodo I., et al. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma. Int J Cancer 2008, 123(12):2915-2922.
92. Oh S., Stish B.J., Sachdev D., Chen H., Dudek A.Z., Vallera D.A. A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res 2009, 15(19):6137-6147.
93. Shimamura T., Royal R.E., Kioi M., Nakajima A., Husain S.R., Puri R.K. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res 2007, 67(20):9903-9912.
94. Weber F., Asher A., Bucholz R., Berger M., Prados M., Chang S., et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64(1-2):125-137.
95. Kreitman R.J., Puri R.K., Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA 1994, 91(15):6889-6893.
96. NCT00014677 https://clinicaltrials.gov/ct2/show/NCT00014677.
97. Seto K., Shoda J., Horibe T., Warabi E., Ishige K., Yamagata K., et al. Interleukin-4 receptor alpha-based hybrid peptide effectively induces antitumor activity in head and neck squamous cell carcinoma. Oncol Rep 2013, 29(6):2147-2153.
98. Seto K., Shoda J., Horibe T., Warabi E., Kohno M., Yanagawa T., et al. Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. Int J Hepatol 2014, 2014:584650.
99. Yang L., Horibe T., Kohno M., Haramoto M., Ohara K., Puri R.K., et al. Targeting interleukin-4 receptor alpha with hybrid peptide for effective cancer therapy. Mol Cancer Ther 2012, 11(1):235-243.
100. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303(5665):1818-1822.
101. Yang F.Y., Wong T.T., Teng M.C., Liu R.S., Lu M., Liang H.F., et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. J Control Release: Off J Control Release Soc 2012, 160(3):652-658.
102. Debinski W., Obiri N.I., Pastan I., Puri R.K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995, 270(28):16775-16780.
103. Joshi B.H., Puri R.K. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif 2005, 39(2):189-198.
104. Husain S.R., Puri R.K. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 2000, 95(11):3506-3513.
105. Kawakami K., Husain S.R., Bright R.K., Puri R.K. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther 2001, 8(11):861-868.
106. Maini A., Hillman G., Haas G.P., Wang C.Y., Montecillo E., Hamzavi F., et al. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol 1997, 158(3 Pt 1):948-953.
107. Kawakami M., Kawakami K., Puri R.K. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002, 1(12):999-1007.
108. Obiri N.I., Husain S.R., Debinski W., Puri R.K. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res: Off J Am Assoc Cancer Res 1996, 2(10):1743-1749.
109. Kawakami K., Kawakami M., Liu Q., Puri R.K. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines. Int J Radiat Oncol Biol Phys 2005, 63(1):230-237.
110. Kawakami K., Husain S.R., Kawakami M., Puri R.K. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002, 8(8):487-494.
111. Kawakami K., Joshi B.H., Puri R.K. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin- induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther 2000, 11(13):1829-1835. [In Process Citation].
112. Kawakami K., Kawakami M., Joshi B.H., Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001, 61(16):6194-6200.
113. Kawakami K., Kawakami M., Puri R.K. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol 2002, 169(12):7119-7126.
114. Kawakami K., Kawakami M., Snoy P.J., Husain S.R., Puri R.K. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001, 194(12):1743-1754.
115. Kunwar S., Chang S., Westphal M., Vogelbaum M., Sampson J., Barnett G., et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-oncol 2010, 12(8):871-881.
116. Kunwar S., Prados M.D., Chang S.M., Berger M.S., Lang F.F., Piepmeier J.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol: Off J Am Soc Clin Oncol 2007, 25(7):837-844.
117. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 2007; 61(5): 1031-7 [discussion 1037-1038].
118. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345(8956):1008-1012.
119. Healy A.T., Vogelbaum M.A. Convection-enhanced drug delivery for gliomas. Surg Neurol Int 2015, 6(Suppl 1):S59-S67.
120. Mueller S., Polley M.Y., Lee B., Kunwar S., Pedain C., Wembacher-Schroder E., et al. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 2011, 101(2):267-277.
121. Suzuki A., Leland P., Kobayashi H., Choyke P.L., Jagoda E.M., Inoue T., et al. Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an orthotopic mouse model of human glioma. J Nucl Med: Off Publ, Soc Nucl Med 2014, 55(8):1323-1329.
122. Ou W., Marino M.P., Suzuki A., Joshi B., Husain S.R., Maisner A., et al. Specific targeting of human interleukin (IL)-13 receptor alpha2-positive cells with lentiviral vectors displaying IL-13. Human Gene Ther Meth 2012, 23(2):137-147.
123. Ulasov I.V., Tyler M.A., Han Y., Glasgow J.N., Lesniak M.S. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 2007, 18(2):118-129.
124. Zhou G., Ye G.J., Debinski W., Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 2002, 99(23):15124-15129.
125. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57(20):4593-4599.
126. Bindon C.I., Hale G., Bruggemann M., Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988, 168(1):127-142.
127. Kioi M., Seetharam S., Puri R.K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 2008, 7(6):1579-1587.
128. Pandya H., Gibo D.M., Garg S., Kridel S., Debinski W. An interleukin 13 receptor alpha 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro-oncol 2012, 14(1):6-18.
129. Balyasnikova I.V., Wainwright D.A., Solomaha E., Lee G., Han Y., Thaci B., et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. J Biol Chem 2012, 287(36):30215-30227.
130. Kawakami K., Terabe M., Kawakami M., Berzofsky J.A., Puri R.K. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res 2006, 66(8):4434-4442.
131. Nakashima H., Fujisawa T., Husain S.R., Puri R.K. Interleukin-13 receptor alpha2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J Translational Med 2010, 8:116.
132. Iwami K., Shimato S., Ohno M., Okada H., Nakahara N., Sato Y., et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 2012, 14(6):733-742.
133. Shimato S., Natsume A., Wakabayashi T., Tsujimura K., Nakahara N., Ishii J., et al. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J Neurosurg 2008, 109(1):117-122.
134. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol: Off J Am Soc Clin Oncol 2011, 29(3):330-336.
135. Saikali S., Avril T., Collet B., Hamlat A., Bansard J.Y., Drenou B., et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 2007, 81(2):139-148.
136. NCT01280552 http://clinicaltrials.gov/show/NCT01280552.
137. Pollack I.F., Jakacki R.I., Butterfield L.H., Hamilton R.L., Panigrahy A., Potter D.M., et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol: Off J Am Soc Clin Oncol 2014, 32(19):2050-2058.
138. Ho W.Y., Blattman J.N., Dossett M.L., Yee C., Greenberg P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003, 3(5):431-437.
139. Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991, 64(5):891-901.
140. Letourneur F., Klausner R.D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci USA 1991, 88(20):8905-8909.
141. Romeo C., Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991, 64(5):1037-1046.
142. June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009, 9(10):704-716.
143. Cartellieri M., Bachmann M., Feldmann A., Bippes C., Stamova S., Wehner R., et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010, 2010:956304.
144. Finney H.M., Lawson A.D., Bebbington C.R., Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998, 161(6):2791-2797.
145. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Translational Med 2011, 3(95). 95ra73.
146. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102.
147. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 2011, 365(8):725-733.
148. Kahlon K.S., Brown C., Cooper L.J., Raubitschek A., Forman S.J., Jensen M.C. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64(24):9160-9166.
149. Brown C.E., Starr R., Aguilar B., Shami A.F., Martinez C., D'Apuzzo M., et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18(8):2199-2209.
150. Kong S., Sengupta S., Tyler B., Bais A.J., Ma Q., Doucette S., et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18(21):5949-5960.
151. Krebs S., Chow K.K., Yi Z., Rodriguez-Cruz T., Hegde M., Gerken C., et al. T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. Cytotherapy 2014, 16(8):1121-1131.
152. Thaci B., Brown C.E., Binello E., Werbaneth K., Sampath P., Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-oncol 2014, 16(10):1304-1312.
153. NCT00730613 https://clinicaltrials.gov/ct2/show/NCT00730613?term=zetakine%26rank=2.
154. NCT01082926 https://clinicaltrials.gov/ct2/show/NCT01082926?term=Zetakine%26rank=1.